Join our daily newsletter At The Bell to receive exclusive market insights
Algorae Pharmaceuticals (ASX:1AI) has this week signed a major exclusive commercial licensing agreement with Sakar Healthcare, with aims to now launch five oncology medicines in Australia and New Zealand.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The September agreement represents Algorae’s first commercial entry into the region, complementing its research and development programs.
The deal will see the company bring five generic oncology medicines to the Australian and New Zealand markets. According to Algorae, the combined addressable market for these products is estimated at approximately $10 million each year. Regulatory planning for Therapeutic Goods Administration approval has commenced, with the company to provide shareholders with further updates on approval timelines and expected revenue contributions as the program progresses.
Sakar Healthcare, headquartered in Ahmedabad, India, is a pharmaceutical manufacturer with EU-GMP and WHO-GMP certified facilities. Its portfolio spans sterile injectables, oral dosage forms, and dry powder injectables, with exports to more than 60 countries across Europe, Asia, Africa, and Latin America.
Algorae confirmed representatives conducted due diligence on Sakar’s facilities, including site inspections and meetings with management and technical staff, to ensure production capacity, quality systems, and regulatory compliance.
The agreement builds on Algorae’s broader oncology strategy, which includes a validation program at the Peter MacCallum Cancer Centre in Melbourne.
That particular program is evaluating 21 oncology drug targets generated by Algorae’s proprietary artificial intelligence (AI) drug discovery platform, AlgoraeOS. Results are expected in the fourth quarter of 2025.
Algorae’s chief commercial officer, Vishal Shah, described the arrangement as the company’s “first commercial deal for the Australian and New Zealand markets,” highlighting that the products will be marketed under the Algorae brand.
Sakar managing director Sanjay Shah added that the partnership will go some way to combining Sakar’s manufacturing expertise with Algorae’s commercial capabilities, supporting improved access across the regions.
Through its wholly owned subsidiary AlgoraeRx Pty Ltd, the company is advancing multiple commercial initiatives alongside its AI-driven drug discovery platform. Algorae stated it will continue to update shareholders on the progress of both commercial and research activities as milestones are achieved.
Before this morning’s bell, 1AI stocks are 0.8 cents each.
Join the discussion. See what HotCopper users are saying about Algae Pharmaceuticals Limited and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
-1200x645-380x200.jpg)
